Background--Autologous adipose tissue-derived mesenchymal stem cells (ATMSCs) therapy is a promising strategy to improve post-myocardial infarction outcomes. In a porcine model of acute myocardial infarction, we studied the long-term effects and the mechanisms involved in allogeneic ATMSCs administration on myocardial performance.
S tem cell therapy has taken on the ambitious objective of regenerating the myocardium after acute myocardial infarction (AMI). Although complete functional regeneration has not been achieved, diverse stem cell lineages have shown properties that result in important beneficial effects in the infarcted myocardium. [1] [2] [3] [4] In this context, adipose tissuederived mesenchymal stem cells (ATMSCs) have shown remarkable outcomes in small-animal studies, [5] [6] [7] ameliorating adverse cardiac remodeling and improving ventricular function and myocardial vascularization. These findings could be related to secretion of anti-apoptotic, pro-angiogenic, and anti-inflammatory cytokines and growth factors. Some of these therapeutic mechanisms have been described in vitro and using small-animal models, [8] [9] [10] but no experiments in large animals have evaluated the early mechanisms involved in the long-term outcomes. Moreover, although our group has reported better benefits of ATMSCs intracoronary administration immediately after the reperfusion, 11 the ideal dosage, route, and timing for cell administration remains unresolved. 12 Furthermore, as AMI is unpredictable, allogeneic stem cells must always be immediately available when needed. Preclinical studies 13 and the POSEIDON (Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis) trial 14 have found allogeneic cell delivery to be as safe and effective as therapies using autologous sources. Nevertheless, long-term cardiac benefits of allogeneic ATMSCs therapy on reperfused hearts must be studied at length in large-animal models of AMI before the treatment can advance to the clinical phase. Therefore, the aim of the present study was to analyze the short-and long-term effects of allogeneic ATMSCs therapy on immune response, myocardial vascularization, and cardiac function and perfusion assessed by cardiac magnetic resonance (CMR), as well as the mechanisms involved, in a translational porcine model of AMI.
Methods
The study protocol was approved by the Animal Experimentation Ethics Committee of the National Center for Cardiovascular Research (Spanish acronym, CNIC) following the Communities Council Directive 2010/63/UE and Spanish (RD 53/2013) regulations related to the Guide for the Care and Use of Laboratory Animals.
Study Design
A total of 41 Large White pigs were used in this study. Three male pigs (56.5AE2.2 kg; 5-6 months old) served as adipose tissue donors and 38 female pigs (35.1AE2.7 kg; 3-4 months old) underwent a reperfused AMI after 50-minute occlusion of the left anterior descending (LAD) coronary artery. Four animals died during the procedure; the 34 remaining animals were randomized into experimental (ATMSCs-treated) and control (vehicle-treated) groups stratified by follow-up: shortterm follow-up (2 days post-AMI), ATMSCs (n=10) and vehicle (n=10); and long-term follow-up (60 days post-AMI), ATMSCs (n=7) and vehicle (n=7). One ATMSCs animal assigned to short-term follow-up was excluded from analysis because of incomplete reperfusion attributable to technical failure, leaving 9 animals in this group and a total of 33 animals in the analysis ( Figure 1A ). Protocol timelines for molecular, imaging, and histological analysis are summarized in Figure 1B .
Subcutaneous Adipose Tissue Collection and Cell Isolation, Culture, and Labeling
Subcutaneous adipose tissue from donor animals was excised from the ventral neck area and kept at 4°C in phosphatebuffered saline (Sigma-Aldrich, St. Louis, MO) supplemented with 1% penicillin/streptomycin (Gibco, Grand Island, NY). Cells were isolated and cultured as described previously. 11, 15 The cells were expanded in a-minimal essential medium (SigmaAldrich) supplemented with 10% fetal bovine serum, 1 mmol/L L-glutamine, and 1% penicillin/streptomycin (Gibco), and 5 lg/ mL Plasmocin TM (Invitrogen) under standard culture conditions (37°C, 5% CO 2 ), with medium replacement every 3 days. Thirdpassage cells were labeled by transduction (2910 6 transducing units/mL multiplicity of infection=21, 48 hours) with a lentiviral vector containing enhanced green fluorescent protein (GFP) under constitutive transcriptional control. 16 Cells expressing GFP were selected by fluorescence-activated cell sorting and frozen before in vivo administration.
AMI Procedure and Intracoronary Administration
The same day of the intervention, animals received oral clopidogrel (150 mg/animal). Antiaggregant therapy was continued 2 days after the AMI induction (clopidogrel 75 mg/animal per day). Anesthesia was induced by an intramuscular injection of ketamine (20 mg/kg), xylazine (2 mg/kg), and midazolam (0.5 mg/kg) and maintained with continuous intravenous infusion of ketamine (2 mg/kg per hour), xylazine (0.2 mg/kg per hour), and midazolam (0.2 mg/kg per hour) and by analgesia with intravenous fentanyl (0.007 mg/kg per hour). Animals were intubated and supportive mechanical ventilation was maintained during the AMI procedure. Sheaths (6F) were percutaneously placed in the femoral artery and vein for drug administration and blood collection, and a heparin bolus of 9000 IU was given before coronary catheterization. AMI was then induced as previously described. [17] [18] [19] Briefly, the LAD was cannulated with a 5F guide catheter, by which a coaxial balloon catheter was advanced past the first diagonal branch. Once placed, the balloon was inflated at low pressure and ischemia was maintained for 50 minutes. LAD occlusion was confirmed angiographically. During ischemia, a continuous infusion of amiodarone (5.5 mg/kg per hour) was administered to prevent malignant ventricular arrhythmias. A biphasic defibrillator was used in case of ventricular fibrillation episodes. After 50 minutes occlusion, the balloon was deflated. Fifteen minutes after reperfusion, 10 7 ATMSCs suspended in 14 mL of Dulbecco's Modified Eagle Medium or Dulbecco's Modified Eagle Medium without cells, depending on the study group, were administered through the coaxial catheter. In order to minimize ischemia during the intracoronary delivery, 7 boluses of 2 mL (1 mL/min) Dulbecco's Modified Eagle Medium with the balloon inflated were interspersed with 2-minute periods of blood flow restoration with the balloon deflated.
Cardiac Imaging Studies
All cardiac imaging studies were performed with the animals under anesthesia. In the short-term follow-up groups, a computed tomography (CT) 64-slice scanner (Brilliance iCT; Philips Medical Systems, Best, The Netherlands) was used to evaluate LAD patency before euthanizing the animals (Figure 1B) . Analysis of CT images was performed on a dedicated advanced image processing workstation (Extended Brilliance Workspace 3.5; Philips Medical Systems, Cleveland, OH) by 2 independent blinded investigators using mainly multiplanar reconstructions. In the long-term follow-up groups, CMR study was performed at 7 and 60 days ( Figure 1B ) with an Achieva 3T-TX whole-body scanner (Philips Healthcare, Best, The Netherlands) equipped with a 32-element phased-array cardiac coil as previously described. 20 Each study consisted of a cine steady-state free-precision sequence to determine left-ventricular end-diastolic volume, left-ventricular endsystolic volume, and left ventricular ejection fraction 21 ; late gadolinium-enhanced sequence to determine infarct size and microvascular obstruction (MVO); and (only at the 7-day CMR) a T2-weighted short-tau inversion recovery sequence to determine the extent of myocardial edema. 21 Absolute cardiac perfusion was estimated using dynamic acquisition with dual-saturation (TS=20, 80 ms) technique to avoid signal saturation during gadolinium-based contrast administration. 22 After perfusion maps generation, region-of-interest analysis was done at the infarcted core, infarct borders (anterior wall and septum), and remote myocardium. Images were analyzed by 2 independent blinded investigators, and processed with analysis software (QMass MR 7.5; Medis, Leiden, The Netherlands and MR Extended Work Space 2.6; Philips Healthcare) as previously described. 21 In case of lack of agreement between the conclusions of the 2 investigators, the discordant images were reviewed by a third blinded investigator.
Assessment of Circulating Cytokines and DonorSpecific Antibodies
In the short-term follow-up groups, blood samples were obtained at baseline before AMI induction and at 2 days post-AMI. In the long-term follow-up groups, blood sampling was carried out at baseline and at 7, 21, and 60 days post-AMI ( Figure 1B) . In a randomized subset of animals (short-term follow-up groups, 7 vehicle and 8 ATMSCs-treated; long-term follow-up groups, 5 vehicle and 5 ATMSCs-treated), serum quantification of interleukin-10 (IL-10) and granulocytemacrophage colony-stimulating factor (GM-CSF) was performed with the cytokine multiplex assay (Quantibody â Porcine Cytokine Array 1; RayBiotech, Norcross, GA). In addition, circulating levels of stromal-derived factor-1a (SDF1a) and hepatocyte growth factor (HGF) were assessed in 5 animals from each of the 4 groups using pig SDF-1a and HGF ELISA kits, respectively (Cusabio Biotech, Wuhan, China). All protocols were performed according to manufacturer instructions. To analyze antibody-mediated rejection, crossmatch tests were performed on serum samples from ATMSCstreated animals in the long-term follow-up group at 21 and 60 days, as previously described.
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Tissue Harvesting
At 2 (short-term follow-up groups) or 60 days (long-term follow-up groups), animals were euthanized and hearts were harvested ( Figure 1B ). Hearts were cut into transversal slices and representative sections were obtained from the anterior core infarcted wall, septum and anterior border zones, and remote posterior wall of the left ventricle. Tissue samples were fixed with 4% formaldehyde and embedded in paraffin for histological studies as previously reported. 15 Tissue samples for molecular biology studies were maintained in Allprotect Tissue Reagent (Qiagen, Hilden, Germany) until storage at À80°C. Samples were also collected from lung, thoracic lymphatic nodes, liver, jejunum, spleen, and kidney for histological and molecular analysis to track delivered GFPATMSCs.
Histology
Histological analysis was performed on 4-lm sections of paraffin-embedded specimens. ATMSCs retention in the infarcted myocardium and border zones was determined by immunofluorescence, using chicken anti-GFP total macrophages with CD107a (1:100, MCA2315GA; Bio-Rad, Kidlington, UK), and the M2-polarized subgroup with CD163 (1:100, bs2527R; Bioss, Beijing, China) antibodies. Collagen deposition in the remote area and the infarct zone was determined by picrosirius red staining. Stained samples from the infarct zone were also analyzed with circularly polarized light to determine collagen I and III.
All histological analyses were performed by 2 independent blinded investigators.
Quantitative Real-Time Polymerase Chain Reaction mRNA expression of GFP, IL-10, HGF, GM-CSF, SDF-1a, vascular endothelial growth factor (VEGF), hepatocyte growth factor receptor, extracellular signal-regulated kinase 1, and secreted frizzled-related protein 2 were determined in the central infarct zone by quantitative real-time polymerase chain reaction (qPCR), based on SYBR â Green fluorescence as previously described. 23 qPCR was performed using the ViiA TM 7 Real-Time PCR System (Applied Biosystems, Foster City, CA). Primer sequences used are described in Table 1 .
Real-Time PCR for GFP mRNA Quantification
The GFP mRNA in infarcted myocardium and border zones was quantified using SYBR â Green-based real-time PCR protocol. Reverse-transcribed GFP cDNA was amplified, starting with 100 ng of total cDNA and using the primer pair 
Results
AMI Procedure and Mortality
At 2 days post-AMI, LAD angiography revealed occlusion, induced by a technical failure, in only 1 of the 20 animals assessed by CT. This animal was excluded from analyses. During the first 48 hours after AMI induction, 4 animals died 
ACTB indicates actin beta; CSF, colony-stimulating factor; HGF, hepatocyte growth factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-10, interleukin-10; MAPK3, mitogenactivated protein kinase 3; MET, MET proto-oncogene; RT-PCR, reverse transcription polymerase chain reaction; SDF-1a, stromal-derived factor-1a; SFRP2, secreted frizzled-related protein 2.
(10.5%, without significant differences between study groups) ( Figure 1A ). One animal (ATMSCs group) died during AMI induction because of malignant arrhythmia. Three more animals (1 from control group, 2 from ATMSCs group) died post-AMI in the animal facilities, presumably because of malignant arrhythmia related to AMI.
Effectiveness and Safety of Cell Delivery
Myocardial ATMSCs engraftment after intracoronary administration was evaluated by GFP tissue detection in the short-term (2 days) and long-term (60 days) groups. Immunohistochemical analysis showed 4AE3 GFP-positive cells per histological section both in the infarcted myocardium and border zone at 2 days post-AMI ( Figure 3 ). GFP expression was also detected by qPCR in the infarcted tissue (21.17AE12.0 copies of GFP) and more markedly in the border zone (96.07AE35.7 copies of GFP). Moreover, 30.9% of the observed GFP-positive cells were terminal deoxynucleotidyl transferase TdT-mediated dUTP nickend-labeling-positive. In the long-term groups, we found no GFP-positive cells in the histological study and detected no GFP gene signal by qPCR. No sign of engrafted GFP-positive cells was detected in remote organs in any group. Inflammatory infiltration was evaluated by histological analysis at 2 days in the short-term groups and at 60 days in the long-term groups. Table 2 shows the number of lymphocytes T and macrophages found in the infarcted myocardium and at the border zone. No significant differences were observed between groups. However, at 60 days, an elevated number of T lymphocytes was observed in 2 animals (483.6 and 1085.5 CD3-positive cells/mm 2 ) receiving ATMSCs, and 1 of them was also crossmatch test positive for humoral immunity. No donor-specific antibodies in serum were found in the other 6 animals receiving allogeneic ATMSCs at 60 days post-AMI. No coronary artery vasospasm was detected while administering the ATMSCs. MVO was assessed by CMR in the longterm follow-up groups at 7 days post-AMI as safety end point. No significant differences were observed between vehicle animals and those receiving ATMSCs (6.0AE8.1% versus 6.2AE7.2% of infarct, respectively; P=0.960).
Vascular Density
Vascular density was similar in both short-term follow-up groups (49.1AE9.1 in vehicle versus 57.1AE15.1 <15-lm vessels/mm 2 in ATMSCs; P=0.176). In contrast, in the long-term follow-up groups, a significant increase in small vessels was detected in the infarct border zones of animals treated with ATMSCs, compared with vehicle-treated (118AE18 versus 92.4AE24.3 <15-lm vessels/mm 2 , respectively; P=0.045) ( Figure 4A ).
Cardiac Function, Edema, Infarct Tissue, and Perfusion by CMR Imaging
CMR values from the long-term follow-up groups are summarized in Table 3 . At 7 days, no statistical differences were observed between vehicle and ATMSCs groups in the infarct size normalized by edema extent, as determined by CMR (0.96AE0.04 versus 0.95AE0.06, respectively; P=1.000). At 60-day follow-up, scar size was also similar between vehicle and ATMSCs-treated animals (19.1AE4.3% versus 15.4AE4.7% of left ventricle, respectively; P=0.153) ( Figure 5 ). Left ventricle functionality study showed no significant differences between groups at 7 or at 60 days in terms of leftventricular end-diastolic volume, left ventricular end-systolic volume, or left-ventricular ejection fraction. Myocardial perfusion of the anterior infarct border was significantly higher 7 days after the intervention in the animals treated with ATMSCs, compared with the vehicle group (87.9AE28.7 versus 57.4AE17.7 mL/min per gram, respectively; P=0.034). This difference was remarkably higher at 60 days post-AMI (99AE22.6 versus 43.3AE14.7 mL/min per gram; P=0.0001) ( Figure 4B ).
Mechanisms Involved in ATMSCs Effects
Pro-angiogenic factors
The studies of pro-angiogenic mechanisms revealed a higher expression of SDF-1a and GM-CSF genes in the infarcted tissue of ATMSCs-treated animals, compared with vehicle-treated, at 2 days. VEGF was also augmented in the infarct zone in the ATMSCs group ( Figure 4C ). Nevertheless, at 60 days, no significant differences in SDF-1a, VEGF, and GM-CSF genes expression were observed among groups.
Analysis of circulating pro-angiogenic factors in the serum showed a significant increase in GM-CSF at 2 days post-AMI in animals treated with ATMSCs, compared with vehicle (1.69AE1.08 versus 0.05AE0.62 log2 fold change, respectively; P=0.003). However, decreased GM-CSF was detected in serum of ATMSCs-treated animals, compared with vehicletreated, at 7 (À0.32AE0.32 versus 0.35AE0.15 log2 fold change, respectively; P=0.003) and 60 days (À0.93AE0.81 versus 1.15AE0.93 log2 fold change, respectively; P=0.006). Dynamics of circulating SDF-1a were similar between groups at short-and long-term follow-up ( Figure 6 ).
Anti-apoptotic effects
The percentage of apoptotic cells in the infarct zone was significantly lower in the ATMSCs-treated animals compared with vehicle at 2 days post-AMI (48.6AE6% versus 55.9AE5.7%, respectively; P=0.017). No differences between groups were observed in the border zone ( Figure 7A ). Study of antiapoptotic pathways showed a significant increase in circulating HGF levels in the ATMSCs group ( Figure 7B ). Moreover, hepatocyte growth factor receptor, extracellular signal-regulated kinase 1, and secreted frizzled-related protein 2 genes were up-regulated in the infarcted myocardium of ATMSCstreated animals ( Figure 7C ). At 60 days, there were no differences in hepatocyte growth factor receptor, extracellular signal-regulated kinase 1, and secreted frizzled-related protein 2 genes expression between vehicle and ATMSCs groups. HGF gene expression was similar at 2 and 60 days post-AMI in the infarcted tissue of both vehicle and ATMSCs-treated animals. The long-term follow-up groups were also similar in their circulating HGF dynamic ( Figure 7B ).
Anti-inflammatory mechanisms
The analysis of possible anti-inflammatory mechanisms at 2 days post-AMI showed a significantly higher percentage of alternatively activated M2 (CD163-positive) macrophages with respect to total number of (CD107a-positive) macrophages in the infarct zone of ATMSCs-treated animals, compared with vehicle-treated (67.2AE10% versus 54.7AE10.2%, respectively; P=0.016) ( Figure 8A ). A higher expression of IL-10 gene was observed in the infarcted tissue of ATMSCs animals, compared with vehicle, in the short-term follow-up groups. Moreover, this anti-inflammatory cytokine (IL-10) was increased at 2 days in systemic blood of animals treated with ATMSCs ( Figure 8B ). In the long-term follow-up groups, a significant increase in the circulating IL-10 was found in the ATMSCs group only at 60-day follow-up (0.99AE2.67 versus vehicle, À3.64AE3 log2 fold change, respectively; P=0.032). Nevertheless, no significant differences were observed in the expression of IL-10 gene in the infarcted tissue ( Figure 8C ).
Effect on collagen deposition
Histological assessment of left ventricle remodeling at 60 days showed no differences in collagen deposition in the remote zone between vehicle and ATMSCs groups (6.3AE1% versus 6.6AE0.6% of area, respectively; P=0.525) or at the scar (38.8AE10.6% versus 41.7AE8.7% of area, respectively; P=0.597). Nevertheless, the collagen type I/type III ratio of the scar was significantly higher in ATMSCs-treated animals, compared with vehicle (1.5AE0.2% versus 2.4AE0.7% of area, respectively; P=0.010) (Figure 9 ).
Discussion
The present study analyzed the long-term outcomes and potential mechanisms of allogeneic ATMSCs therapy in a translational porcine model of reperfused AMI. The main finding of our work was that allogeneic ATMSCs administration promoted an increase in myocardial perfusion in the ischemic tissue of animals with AMI. Moreover, a decrease in the apoptotic process and an up-regulation of anti-inflammatory and reparative mechanisms have been identified in the short-term after ATMSCs administration.
Intracoronary Delivery of Allogeneic ATMSCs
Intracoronary administration is one of the least invasive delivery methods, although infusion of large-size adult mesenchymal stem cells (MSCs) (up to 20 lm in diameter) could potentially obstruct capillaries (from 6 to 10 lm in diameter), leading to permanent no-reflow phenomena after cell administration. In this sense, clinical 24 and preclinical [25] [26] [27] [28] [29] studies have found that intracoronary injection of a significant number (up to 50 million) of large-size stem cells (%20-50 lm in diameter) can be safe when administered a few days after AMI. However, microvascular injury is higher during the first 24 hours post-AMI, and therefore the probability of capillary plugging and MVO increases when administering large cells directly into the culprit artery. Although MVO persists at least 1 week after reperfusion, 30 our study found no MVO increase at 7 days post-AMI in those animals receiving 10 7 ATMSCs (%13 lm in diameter) in the LAD just after reperfusion. Our finding agrees with most of the previous literature 11, 27, 31 and supports the feasibility and safety of intracoronary administration of large-size cells just after reperfusion as long as precautions are taken in determining the infusion rate and dose. The protocol of cell administration just after reperfusion requires rapid availability of ATMSCs; the cells must be stored to use when needed and, consequently, allogeneic origin is required. An important advantage of administering allogeneic stem cells is that they could be obtained from healthy young donors, since quantitative and qualitative stem cell deterioration has been demonstrated in aged patients 32 with atherosclerotic risk factors. 33 
Host Response
Originally, MSCs were described as possessing an immunoprivileged status and immunosuppressive properties, 34 which could present an advantage for allogeneic cell therapies. In our porcine model, no significant differences between groups were observed in immune cells infiltration after cell therapy; however, 2 animals receiving allogeneic ATMSCs had increased T-lymphocyte infiltration at 60 days, which could reflect interindividual variations in the response. Moreover, only 1 of the 7 animals receiving allogeneic ATMSCs produced allo-antibodies, which agrees with the host response observed in our previous study in the same animal model 11 and a previously reported clinical trial 14 using allogeneic MSCs.
Conversely, Kanazawa 35 reported the absence of humoral rejection after in vivo administration of allogeneic cardiosphere-derived cells, which could be explained by differences in source-dependent characteristics described by Ock et al. 36 
Insights Into ATMSCs Modulation of Endogenous Reparative Process and Inflammatory Response
Two days after administration, one third of implanted ATMSCs were already in apoptosis and no signal of ATMSCs presence was detected in the infarcted tissue at long-term follow-up. Nevertheless, major benefits after ATMSCs therapy were observed at 60 days, suggesting that the long-term benefits observed in our study are a consequence of changes promoted by ATMSCs in the acute phase after their administration. To test this hypothesis, we evaluated some of the mechanisms involved in the repair process and stimulation of endogenous stem cell population. In particular, we found an increase in the chemotactic mediators SDF-1a and GM-CSF at 2 days after cell administration. As previously proposed, 11, 37 we would further hypothesize that endogenous stem cell stimulation could increase and continue to support the regenerative mechanisms promoted by MSC therapy, even when these cells were not present in the infarcted tissue.
Accordingly, ATMSCs administration could be described as a booster therapy for the endogenous reparative process. In addition, a qualitative modification to the percentage of antiinflammatory and pro-repair M2 macrophages was detected in our porcine model of AMI. A relationship between ATMSCs and polarization of M2 macrophages has been previously described in vitro 38 and in a porcine model of renal artery stenosis. 39 Our finding was also accompanied by a clear increase in circulating IL-10 and its mRNA in the infarcted tissue in the short term after ATMSCs administration. One of the most important anti-inflammatory mediators, IL-10 is involved in the pro-inflammatory/anti-inflammatory macrophages switch and, therefore, in setting up the reparative phase. 40 
ATMSCs Administration as a Pro-Vascularization Therapy
Improved vascular density 15, 31, 41 and myocardial perfusion 27, 31 have been reported after autologous ATMSCs therapy. In our study, similar outcomes were found but after intracoronary administration of ATMSCs from allogeneic origin. Moreover, we identified an enhancement of 4 mediators (VEGF, HGF, GM-CSF, and SDF-1a) and M2 macrophages involved in neovascularization in the acute phase after cell administration as potential mechanisms in the improvement of myocardial perfusion. Our data suggest that these upregulated pro-angiogenic mechanisms just 2 days after therapy could have an important role in the increase of myocardial perfusion observed at 7-day follow-up. Given the observed trend toward better myocardial perfusion at 60 days, compared to 7 days, we hypothesize that the increase in the pro-angiogenic mediators promoted by ATMSCs therapy not only enhances the initial physiological vessel sprout but also contributes to maintain this newly established microvasculature. In contrast, we observed a significant decrease in myocardial perfusion at 60-day followup in the vehicle group, suggesting a certain loss of the new microvasculature established in the acute post-AMI phase. In this sense, the decrease in the apoptotic process observed after 2 days and propitiated by the ATMSCs therapy could also have an important role in promoting vessel persistence in ATMSCs-treated animals, enhancing vessel density and myocardial perfusion in the longer term.
Our main findings about myocardial vascularization and perfusion could have clinical implications for improving the patient's quality of life, as in the PROGENITOR trial. 3 The earlier clinical study showed an enhancement in myocardial perfusion together with a decrease in the number of angina episodes and improved angina functional class in patients who had refractory angina and who received a transendocardial injection of CD133+ progenitor cells.
Cardiac Function and Remodeling
Despite the lack of any reduction in infarct size or improvement in left ventricular ejection fraction, a lower percentage of apoptotic cells was detected in the infarcted tissue at 2 days after intracoronary cell administration. Our data agree with published studies demonstrating the in vivo antiapoptotic effect of ATMSCs. 42, 43 Furthermore, we described an up-regulation of potential mechanisms related to this early anti-apoptotic effect: an increase in circulating HGF was detected 2 days after ATMSCs administration, as well as an up-regulation of hepatocyte growth factor receptor and extracellular signal-regulated kinase 1 in the infarcted tissue, which are mediators of the HGF signaling pathway. HGF benefits in myocardial infarction have been postulated previously, 44, 45 and its secretion by ATMSCs has been described 5 and reinforced, 46 but these previous studies did not analyze the relationship between ATMSCs therapy and an increase in systemic circulation of HGF in a clinically relevant AMI model. In the animals receiving ATMSCs, we also identified an up-regulation of the secreted frizzled-related protein 2 gene, an anti-apoptotic mediator that is secreted by MSCs and exerts cardiac protection. 47 However, despite the 10% reduction in the apoptotic process observed at 2 days post-AMI, this effect was not sufficient to reduce infarct size or enhance left ventricular ejection fraction. Although no reduction in scar size was observed by CMR, histological analysis detected a higher ratio of type I/type III collagen in the infarcted tissue at 60 days, suggesting the establishment of a more mature and stiffer scar in the animals treated with ATMSCs. In a knock-out MMP9 mouse model of myocardial infarction, Voorhees et al 48 reported that a stiffer scar presented better ventricle mechanics, suggesting that a stiffer scar could prevent ventricular dilation. Although the stiffer scar observed in the ATMSCs-treated animals in our study could suggest less susceptibility to infarcted ventricle dilation or scar rupture, more detailed studies with longer follow-up are needed to prove this hypothesis.
Limitations
In this study, we were unable to determine baseline CMR before ATMSCs treatment because of the immediacy of the intracoronary infusion protocol (15 minutes after AMI Figure 9 . Images from picrosirius red staining were obtained with circularly polarized light. Collagen type I (red fibers) was more predominant in the scar from animals treated with ATMSCs than with collagen type III (green fibers). Scale bars, 50 lm. ATMSCs indicates adipose tissue-derived mesenchymal stem cells.
induction). A limitation of all animal studies is that caution is needed when extrapolating experimental results to the clinic. However, the pig is considered one of the most clinically translatable large-animal models for the study of potential therapies in the context of AMI. It has a coronary artery anatomy and distribution similar to that of humans, along with a minimal pre-existing coronary collateral flow. 49 On the other hand, cell labeling-tracking and counting is limited in a large animal because it is methodologically complicated to analyze the entire organ, and thus, we performed the analysis in representative histological samples. Another limitation when using a porcine model is that sedation is required to obtain blood samples, and consequently, the blood sampling protocol was designed considering the risks of increased mortality because of repeated sedations in the nearly days after AMI induction.
Conclusions
In summary, intracoronary administration of allogeneic ATMSC is a safe procedure and promotes the stimulation of reparative pathways, as evidenced by better myocardial vascularization and perfusion in our clinically relevant model of reperfused AMI. Although the short-term mechanisms triggered by delivered ATMSCs were insufficient to modify infarct size and left ventricle function, the local and systemic changes promoted by ATMSCs therapy suggest remarkable assets for future heart regeneration strategies. 
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